Indications for RESTYLANE LYFT:
Correction of moderate-to-severe facial folds and wrinkles (eg, nasolabial folds). Cheek augmentation and correction of age-related midface contour deficiencies. Correction of dorsal hand volume deficit.
See full labeling. Inject slowly with least amount of pressure necessary. Individualize. Wrinkles/folds: inject into the deep dermis to superficial subcutis; max 6mL per treatment. Cheek augmentation/midface deficiencies: (≤21yrs): not established; (>21yrs): give by subcutaneous or supraperiosteal injection; max 6mL per treatment. Dorsal hand volume deficit: (≤21yrs): not established; (>21yrs): inject into the subcutaneous plane; max 3mL/hand per treatment. All: may require repeat treatments to achieve desired effects.
History of anaphylaxis or presence of multiple severe allergies. Allergies to Gram (+) bacterial proteins. Bleeding disorders.
Should only be used by trained and experienced healthcare practitioners. Obtain patient's complete medical history prior to initiation. Avoid intravascular inj; discontinue immediately if changes in vision, signs of stroke, blanching of skin or unusual pain during or shortly after procedure occurs. Avoid implantation in vascular rich areas (eg, glabella, nose) or into tendons in the dorsal hand. Risk of infection. Defer if active inflammatory process or infection is present at specific sites. Use for lip augmentation or in areas other than nasolabial folds, midface area, and dorsal hand: not established. Autoimmune disease of the hand. Hand implants. Dupuytren's contracture. History of hand tumor. Vascular malformations. Raynaud's disease. Risk of tendon rupture. Concomitant epilation, UV irradiation, or laser, mechanical or chemical peeling procedures: not evaluated. Possible risk of an inflammatory reaction at implant site if laser treatment, chemical peeling, or any other procedure based on active dermal response is considered after Restylane Lyft or if product is given before skin has healed completely after such a procedure. Risk of herpes reactivation in patients with a history of herpetic eruption. Avoid excessive sun, UV lamp exposure, or extreme cold weather. Patients (<18yrs), pregnancy, nursing mothers: not established.
Caution with concomitant immunosuppressants or in those who have undergone therapy with thrombolytics, anticoagulants, or platelet aggregation inhibitors in the preceding 3wks. Increased bruising or bleeding at inj sites with concomitant aspirin, NSAIDs, St. John's Wort, high dose Vit. E; avoid.
Inj site reactions (eg, bruising, redness, swelling, pain, tenderness, itching); delayed inflammatory papules, hyperpigmentation, possible keloid formation, hypersensitivity reactions.
Single-use syringe—1 (w. needles)